GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Notes Receivable

NewAmsterdam Pharma Co NV (FRA:KH6) Notes Receivable : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Notes Receivable?

NewAmsterdam Pharma Co NV's Notes Receivable for the quarter that ended in Mar. 2025 was €0.00 Mil.


NewAmsterdam Pharma Co NV Notes Receivable Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Notes Receivable Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - - -

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NewAmsterdam Pharma Co NV Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


NewAmsterdam Pharma Co NV Notes Receivable Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma Co NV Headlines

No Headlines